Revelation Biosciences, Inc. (REVB) stock

REVBNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVBW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$4.26−0.12 (-2.63%)

Close on Nov 13, 2026Market cap $2.91MP/E –Yield –

Revelation Biosciences statistics

52 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 25, 2027 (estimated, during market hours)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $2.91M; $272.32M
Enterprise Value: -$6.21M; $146.23M
PB Ratio: 0.40; 2.00
P/TBV Ratio: 0.40; 2.22

Share statisticsIndustry

Shares Outstanding: 683,442; 58M
Shares Change (QoQ): -82.5%; 0.50%

Short sellingIndustry

Short Interest: 12,792; –
Short Interest Change: 93.7%; -0.80%
Days to Cover: 1.00; 5.15

Stock price statisticsIndustry

52-Week High: $40.60; –
52-Week Low: $3.08; –
20-Day Moving Average: $3.90; –
50-Day Moving Average: $5.16; –
200-Day Moving Average: $7.36; –
Average True Range (14): $0.45; –
Price Change (1 Week): 9.64%; -1.15%
Price Change (1 Month): -20.1%; -4.87%
Price Change (3 Months): -47.0%; -21.0%
Price Change (6 Months): -37.8%; -20.6%
Price Change (YTD): -81.0%; -23.6%
Price Change (1 Year): -84.5%; -22.4%
Price Change (3 Years): -100.0%; -29.5%
Price Change (5 Years): -100.0%; -77.9%
Average Volume (10 Days): 13,559; –
Average Volume (20 Days): 23,534; –
Average Volume (90 Days): 10,450; –
Relative Volume: 0.63; 0.70
Relative Strength Index (14): 48.0; 43.4
Volatility (1 Year): 83.7%; 80.1%
Beta (5 Years): 1.23; 1.07

Returns on capitalIndustry

Return on Equity (ROE): -133.4%; -49.9%
Return on Assets (ROA): -106.3%; -40.6%
Return on Capital Employed (ROCE): -165.2%; -37.9%

Financial positionIndustry

Current Ratio: 3.98; 3.30
Quick Ratio: 3.92; 2.39

EfficiencyIndustry

Profits Per Employee: -$1.52M; -$689.41K
Employee Count: 8; 74
WACC: 11.3%; 10.2%

Income statement (TTM)Industry

Operating Income: -$12.71M; -$21.37M
Net Income: -$12.16M; -$22.35M
EBITDA: -$12.71M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $9.12M; $68.68M
Net Cash (Debt): $9.12M; $17.76M
Net Cash Per Share: $13.35; $0.80
Equity (Book Value): $7.23M; $53.89M
Book Value Per Share: $10.58; $1.50
Tangible Book Value: $7.23M; $27.13M
Working Capital: $6.94M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$10.10M; -$12.38M

Dividends and yieldsIndustry

Earnings Yield: -417.1%; -21.8%

Scores and fair valueIndustry

Altman Z-Score: -10.98; 0.23
Piotroski F-Score: 4; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	REVB	S&P 500	Difference	REVB per year	S&P 500 per year
1 month	-16.6%	-3.0%	−13.5 pts
3 months	-45.1%	-2.8%	−42.3 pts
Year to date	-81.0%	+11.5%	−92.4 pts
1 year	-83.3%	+13.5%	−96.8 pts
3 years	-100.0%	+77.7%	−177.7 pts	-94.3%	+21.1%
5 years	-100.0%	+72.6%	−172.6 pts	-95.0%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M REVB shares were sold short on Oct 30, 2026, up 93.7% from the previous report. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 38.8% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	12,792	+93.7%	39,572	1.0
Oct 15, 2026	6,605	+317.8%	41,123	1.0
Sep 30, 2026	1,581	+517.6%	36,220	1.0
Sep 15, 2026	256	-56.0%	14,833	1.0
Aug 31, 2026	582	-96.2%	61,763	1.0
Aug 14, 2026	15,394	-25.7%	21,146	1.0
Jul 31, 2026	20,729	+2.6%	40,934	1.0
Jul 15, 2026	20,200	+44.9%	58,166	1.0
Jun 30, 2026	13,941	-25.2%	38,868	1.0
Jun 15, 2026	18,630	-29.0%	50,599	1.0
May 29, 2026	26,240	-24.0%	33,045	1.0
May 15, 2026	34,510	+87.5%	81,197	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?